MUC1 and pancreatic neoplasm: revealed that WT1/MUC1-DC vaccination extended the 3-year overall survival rate to 77.8% in the adjuvant setting of pancreatic cancer (37), which awaits to be assessed its clinical advantages in a large-scale trial.